Atypical hemolytic-uremic syndrome due to complement factor I mutation

Figure 2 Serum creatinine levels did not improve despite plasma exchange, and hemodialysis was initiated. Lactate dehydrogenase levels improved with plasma exchange, whereas the platelets showed transient improvement under the plasma exchange treatment. Treatment with eculizumab induced a persistent improvement in platelet count. Continued eculizumab treatment resulted in late renal benefit, with dialysis withdrawn in June 2015. PLEX: Plasma exchange; Scr: Serum creatinine; LDH: Lactate dehydrogenase.